Standardized clinical data capture to describe cerebral palsy

Susie Kim BSc CNA^a, Kelsey Steffen MA^a, Lauren Gottschalk-Henneberry RN^a, Jennifer Miros MPT^b, Katie Leger PNP, Amy Robichaux-Viehoever MD PhD^a, Karen Taca BS^c, Bhooma Aravamuthan MD DPhil^a

Affiliations: ^aDivision of Pediatric Neurology, Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; ^bPhysical Therapy, Therapy and Audiology Services, St. Louis Children's Hospital, St. Louis, MO, USA; ^cPhysician Billing Services, Washington University School of Medicine, St. Louis, MO, USA.

Address correspondence to:

Dr. Bhooma R. Aravamuthan Division of Pediatric Neurology, Department of Neurology Washington University School of Medicine 660 South Euclid Avenue, Campus Box 8111 St. Louis MO 63110-1093 [aravamuthanb@wustl.edu] 314-454-6120

Short title: Clinical data capture to describe CP

Conflict of Interest Disclosures (includes financial disclosures): The authors report no disclosures or conflicts of interest concerning the research related to this manuscript.

Funding/Support: NINDS 1K08NS117850-01A1 (BRA)

Role of Funder/Sponsor: NINDS had no role in the design and conduct of this study.

Abbreviations: ADI – area deprivation index; ASM – anti-seizure medication; CFCS -Communication Function Classification System; CP – cerebral palsy; EDACS - Eating and Drinking Ability Classification System; EHR – electronic health record; G/GJ – gastrostomy/gastrojejunostomy; GMFCS - Gross Motor Functional Classification System; IEP – individualized education plan; IVH – intraventricular hemorrhage; MACS - Manual Ability Classification System; MRICS – MRI Classification System; PVL – periventricular leukomalacia; US – United States of America; VFCS – Visual Function Classification System; VSS – Viking Speech Scale.

Article summary: Using caregiver and clinician-entered data on people seen in a tertiary-care CP center, we determined medical features affecting the odds of three functional outcomes.

What's known on this subject: Detailed CP characterization can be limited if using populationbased registries and retrospective chart review alone, including limited data on recently validated functional classification systems for CP.

What this study adds: We comprehensively captured caregiver and clinician-entered data on 97% of people seen in our CP Center to describe how CP manifests and show that cortical injury and initial ICU stay duration affect the odds of walking, oral feeding, and speech.

Contributors Statement

Susie Kim helped design the study, aggregated data, carried out data analyses, and critically reviewed and revised the manuscript.

Kelsey Steffen helped conceptualize and design the study and critically reviewed and revised the manuscript.

Lauren Gottschalk, Jennifer Miros, Katie Leger, Amy Viehoever, and Karen Taca helped design the study and critically reviewed and revised the manuscript.

Bhooma Aravamuthan conceptualized and designed the study, supervised data collection and analysis, drafted the initial manuscript, and critically reviewed and revised the manuscript.

Abstract

Objective: To describe a standardized methodology for capturing clinically valuable information on young people with cerebral palsy (CP) from caregivers and clinicians during routine clinical care.

Methods: We developed a caregiver-facing intake form and clinician-facing standardized note template and integrated both into routine clinical care at a tertiary care CP center (https://bit.ly/CP-Intake-Methodology). We extracted this caregiver and clinician-entered data on people with an ICD10 diagnosis of CP seen between 3/22/23 and 12/28/23. We used this data to describe how CP manifests in this group and which medical features affected the odds of walking, oral feeding, and speech by age 5.

Results: Of 686 visits, 663 (97%) had caregiver- and clinician-entered data and 633 had a clinician-confirmed CP diagnosis (mean age 9.1, 53.4% Male, 78.5% White). It was common to have quadriplegia (288/613, 47.0%), both spasticity and dystonia (257/632, 40.7%), walk independently (368/633, 58.1%), eat all food and drink safely by mouth (288/578, 55.9%), and produce understandable speech (249/584, 42.6%). Cortical grey matter injury and duration of initial critical care unit stay affected the odds of walking, oral feeding, and speech (binary logistic regression, p<0.001).

Conclusions: We comprehensively captured caregiver and clinician-entered data on 97% of people seen in a tertiary care CP Center and used this data to determine medical features affecting the odds of three functional outcomes. By sharing our methodology, we aim to facilitate replication of this dataset at other sites and grow our understanding of how CP manifests in the US.

Introduction

Cerebral palsy is the most common childhood motor disability, affecting 2 of every 1000 children in the US.¹ Given its high prevalence, it is critical to have a detailed understanding of how CP manifests. The Centers for Disease Control and Prevention last assessed CP prevalence in 2016¹ using retrospective medical record review in targeted geographical regions. This methodology is valuable for collecting broad prevalence data but precludes detailed CP characterization due to variability in clinical documentation practices and the required personnel hours. The Cerebral Palsy Research Network (CPRN) facilitates multi-institutional prospective data entry as a part of clinical workflow,² and currently partners with 35 tertiary care centers (34 in the US)³ to document at least five "essential" items required for all CP care.⁴ This helps identify large subpopulations of people with CP for further detailed analysis but may not provide detailed CP characterization in isolation. National CP registries outside the US have conducted detailed population-based prospective data collection, but typically require significant financial, personnel, and time investments.⁵ Data on more recently validated functional classification systems for CP have yet to be broadly collected in these registries and more specific data like medication history for tone and seizure management are also not typically captured.⁵ Therefore, acknowledging the strengths and gaps of the above approaches, there remains significant value in comprehensive and standardized data capture at large single centers caring for people with CP. Here, we describe our methodology for standardized clinical documentation and prospective data collection in a pediatric tertiary care CP center. We use this data to see which medical factors affect the odds of three functional outcomes: walking, oral feeding, and speech. Our goals are to facilitate recapitulation of our methodology at other sites and contribute to detailed characterization of CP in the US.

Methods

<u>Standard Protocol Approvals, Registrations, and Patient Consents:</u> Human Subjects Research exemption was granted by the Washington University Institutional Review Board (ID#202309003, 09/11/2023).

<u>Creation of the caregiver-facing intake form and clinician standardized note template</u>: Data was collected in the Cerebral Palsy and Mobility Center affiliated with St. Louis Children's Hospital and the Washington University Department of Neurology. The CP Center is staffed by 2 pediatric movement disorders neurologists and a pediatric nurse practitioner with multiple years' experience caring exclusively for people with CP and movement disorders.

The caregiver-facing intake form and clinician note template were designed to include medical issues valuable for CP care as enumerated by the American Academy of Pediatrics Council on Children with Disabilities.⁶

Clinician documentation, exclusively in Epic (Epic Systems Corporation), included:

- Diagnosis (CP or not)
- Predominant and other tone/movements (determined using published descriptions^{7–13} and the Hypertonia Assessment Tool¹⁴)
- Anatomic distribution (e.g. diplegia, quadriplegia)
- Etiology/-ies
- Functional ability using tools validated for CP:
 - Gross Motor Functional Classification System (GMFCS, valid for all ages)^{15,16}
 - Manual Ability Classification System (MACS, age 4+)¹⁷
 - Communication Function Classification System (CFCS, age 2+)¹⁸

- Motor verbal speech assessed using the Viking Speech Scale (VSS, age 4+)¹⁹
- Visual Function Classification System (VFCS, age 1+)²⁰
- Eating and Drinking Ability Classification System (EDACS, age 3+)²¹
- Brain MRI findings (for those with images in the EHR) using the MRI Classification System²² validated for CP.

Caregiver documentation included:

- Demographics (National Institutes of Health Common Data Elements²³)
- Birth history
- Medication and botulinum toxin history for motor/tone management
- Orthotics and equipment
- Therapies
- Medical specialties seen and surgical history
- Seizure history
- Sleep, pain, mood, sensory, and social concerns
- Family history

To avoid diagnostic variability,²⁴ clinicians agreed *a priori* to diagnose CP per the 2006 definition²⁵ in any child with a disturbance to the developing brain sustained before 2 years of age who has or is predicted to have a resultant permanent and non-progressive motor disability.²⁶ Clinicians also agreed to include predominant or pure hypotonia as CP phenotypes, in line with half of CP registries globally.^{5,24} Area Deprivation Index (ADI) was determined using 9-digit zip codes in the EHR.²⁷

The intake form and note template (https://bit.ly/CP-Intake-Methodology) were iteratively revised by all members of the CP Center (including physical and occupational therapists, orthotists, seating and equipment specialists, a social worker, a nurse coordinator, and a certified nurse assistant) between 12/1/2022 and 3/1/23. Between 1/30/23 and 3/22/23, families seen in the CP Center piloted the form and provided their feedback during clinic visits. The intake form and note template were launched as routine clinical workflow on 3/22/2023. Clinician data entry for the MACS, CFCS, VSS, VFCS, and EDACS was additionally launched on 4/15/2023.

Data capture

Inclusion criterion: People seen in the CP Center between 3/22/23 and 12/28/23 with a primary visit ICD10 diagnosis of CP (G80). Exclusion criteria: 1) No clinician-entered Smartlist data; 2) No caregiver-entered intake form data; and 3) Person does not have CP (via clinician-entered Smartlist designation).

Families are sent the intake form via a REDCap link (<u>https://redcap.link/CP-intake-example</u>) provided in a mailed flyer, MyChart message, email, phone call, and secure tablet device in the clinic waiting room. Completed intake form data is exported as a CSV file, converted into a readable format using a mail merge template in Microsoft Word, and then entered in the EHR by a certified nurse assistant (SK). Clinicians can pull this information into their Epic Smartphrase note template and then enter data in the note using Epic Smartlists. Smartlist selections are mapped to Smart Data Elements which populate an Epic Clarity Table for data export (https://bit.ly/CP-Intake-Methodology).

Data analysis

Both clinicians and caregivers were queried about functional abilities, but only clinician-entered functional assessments were used for analysis. For some data elements, caregivers were asked to select all choices that apply, precluding differentiation between missing data and situations where no choices applied (denoted in the Tables as "none indicated"). Missing data percentages were otherwise calculated for each data element.

Data were analyzed descriptively (percentages and means with 95% confidence intervals, CIs) in Microsoft Excel. Binary logistic regression (SPSS, IBM, Armonk, NY) was used to assess whether five variables which can be determined in infancy (ADI, gestational age, birth weight, MRICS brain injury pattern, and etiology) affected the odds of: a) independent ambulation (GMFCS levels I-III vs. levels IV-V), b) ability to take nutrition orally (directly queried), and c) ability to produce verbal speech understandable to unfamiliar listeners (VSS levels I-II vs. levels III-IV).

To ensure that outcome variables were stable when assessed, only data collected for children 5 years and older were used for logistic regression analysis. Chi-square and Wald tests were used to determine significance of the model and model terms, respectively (p<0.05), and the Hosmer-Lemeshow test was used to estimate goodness of model fit (p>0.05). Adjusted odds ratios (ORs) and 95% CIs were calculated.

<u>Data sharing</u>: De-identified data will be shared with qualified investigators upon request. See <u>https://bit.ly/CP-Intake-Methodology</u> for all materials necessary to replicate our methodology.

Results

Of 686 visits meeting inclusion criteria, 663 (97%) had caregiver- and clinician-entered data. Of these, 30 did not have CP, yielding data on 633 people with CP. The median percentage of

missing data across all data elements was 1.9% (range 0-10.4%). Noting that clinicians began routinely entering MACS, CFCS, VSS, VFCS, and EDACS data in the clinical note 24 days into the 281-day data collection period, there is greater percentage of missing data for these functional classification systems (median 9.5%) than for other data (median 0.2%). As an indicator that caregivers completed the intake form fully, the last page of the intake form had a median missing data percentage of 0.8% (range 0.3-3.0%).

Demographics

People with CP were 9.1 years old on average (95% CI 8.3 to 9.9 years old, range 0.5-23.2 years) and 53.6% (337/629) male. Most caregivers (523/629, 83.1%) identified their race and the race of the young person they cared for as White (492/627, 78.5%). A minority of caregivers had a bachelor's degree or higher (251/614, 39.7%). Noting that higher ADIs indicate greater socioeconomic disadvantages, 233/633 (36.8%) had an ADI greater than the 75% ile for the country and 456/633 (72.0%) had an ADI greater than the 50% ile. Families lived an average of 68.1 miles from the CP Center (95% CI 58.5 to 77.8 miles) (Figure 1, Table 1).

Motor tone types, distribution, and functional abilities

The most common tone types were spasticity (533/632, 84.3%), dystonia (369/632, 58.4%), and hypotonia (320/633, 50.6%) with 120/632 (19.0%) having hypotonia as their predominant tone type. Most people had a mixed tone/movement pattern (462/632, 73.1%) even when excluding hypotonia (348/584, 59.6%). The most common presentation was spasticity predominant tone accompanied by dystonia (257/632, 40.7%) (Table 2). Quadriplegia was the most common CP distribution (288/613, 47.0%) followed by diplegia (121/613, 19.7%) (Table 3).

The majority were independently ambulatory (368/633, 58.1%), had minimal manual ability limitations (317/468, 67.7%, at MACS Levels I-II), intact visual function (284/564, 50.4%, at VFCS Level I), and were able to eat all food and drink safely orally (288/515, 55.9%, at EDACS Level I). The majority also had minimal limitations in motor speech output (249/467, 53.3% at VSS levels III and IV) or communication overall (282/539, 52.3% at CFCS levels I and II) (Table 4).

Brain MRI patterns, etiology, and birth history

White matter injury was more common (323/618, 52.3%) than grey matter injury (146/618, 23.6%). A minority had cerebral malformations or maldevelopments (92/618, 14.9%) or a normal brain MRI (59/618, 9.5%) (Table 5).

The single most common CP etiology was prematurity (251/633, 39.7%) followed by genetic/metabolic etiologies (146/633, 23.1%). Of note, 9.2% (58/633) had an unknown etiology, which was typically documented in the absence of neonatal distress (i.e. suggestive of a genetic/metabolic etiology^{28,29}) (Table 5).

Over half were born at or after 37 weeks gestation (322/610, 52.8%), vaginally (315/610, 51.6%), and at a birthweight 2500g or greater (296/584, 50.7%). The majority required ICU admission (470/619, 75.9%) (Table 6).

Motor medications, botulinum toxin, orthotics, equipment, and therapies

The most common medications people with CP had ever taken for motor symptom management were baclofen (221/633, 34.9%), gabapentin (154/633, 24.3%), diazepam (144/633, 22.7%), and clonidine (121/633, 19.1%). The majority had received botulinum toxin injections (333/633, 52.6%), most commonly in the lower legs (248/623, 39.8%) and upper legs (190/623, 30.5%)

(Table 7). The majority wore ankle foot orthoses (458/633 for either left or right, 72.4%) and many used a manual wheelchair (258/633, 40.8%) (Table 8). Most received physical therapy (485/626, 77.5%), occupational therapy (435/626, 69.5%), or speech therapy (369/626, 58.9%), most commonly at school (382/628, 60.8%) via an individualized educational plan (446/627, 71.1%) (Table 9).

Medical specialists, surgeries, and nutrition

The most common non-neurologic specialties regularly seen were ophthalmology (273/633, 43.1%), orthopedic surgery (214/633, 33.8%), gastroenterology (182/633, 28.8%), and neurosurgery (142/633, 22.4%). The most common neurosurgical and orthopedic interventions were ventricular shunt placement (102/633, 16.1%) and lower extremity soft tissue surgery (172/633, 27.2%), respectively. The most common general surgery was gastrostomy/gastrojejunostomy tube placement (208/633, 32.9%), with 30.0% (176/586) receiving nutrition via tube feeding (Table 10).

Seizure history and other co-existing symptoms

The majority had experienced seizures (327/632, 51.7%). Of people taking anti-seizure medications (268/633, 42.3%), the majority were taking levetiracetam (148/268, 55.2%) followed by clobazam (104/268, 38.8%). As an estimate of rates of drug resistant epilepsy,³⁰ 14.4% (83/575) were on at least two anti-seizure medications and had a seizure in the previous 30 days and 8.3% (48/575) were on at least three anti-seizure medications and had a seizure in the previous 30 days. (Table 11).

Many expressed pain concerns (230/629, 36.6%), poor sleep (190/629, 30.0%), anxiety (157/633, 24.8%), and attentional difficulty (156/633, 24.6%). Other concerns included

avoidance or seeking of loud noises (195/633, 30.8%) and struggling to accept changes in routine (166/633, 26.2%) (Table 12).

Family history

A minority had siblings with health concerns (107/610, 17.5%), most commonly attentional difficulties (26/610, 4.3%), autism (19/610, 3.1%), or CP or other motor conditions (18/610, 3.0%). Family history was otherwise notable for autism (70/633, 11.1%), CP (46/633, 7.3%), and seizures/epilepsy (45/633, 7.1%) (Table 13).

Variables affecting the odds of independent ambulation, oral nutritive feeding, and speech

Binary logistic regression revealed good model fits when assessing whether five variables (ADI, gestational age, birth weight, MRICS brain injury pattern, or etiology) affected the odds of each of three outcomes: independent ambulation (Hosmer-Lemeshow p=0.96, Chi-square p<0.001), the ability to take nutrition orally (Hosmer-Lemeshow p=0.46, Chi-square p<0.001), and the motor ability to produce understandable speech (Hosmer-Lemeshow p=0.75, Chi-square p<0.001) by 5 years old.

Variables that decreased the odds of independent walking were cortical grey matter injury (OR 3.9, 95% CI 1.4-11.3, p=0.01), cerebral malformations (OR 3.5, 95% CI 1.3-9.7, p=0.02), basal ganglia or thalamic injury (OR 7.9, 95% CI 1.7-36.1, p=0.007), infection as a CP etiology (OR 11.6, 95% CI 2.0-66.8, p=0.006), and initial ICU stay between 1-3 months (OR 3.4, 95% CI 1.3-8.7, p=0.01), 4-6 months (OR 6.4, 95% CI 1.8-22.8, p=0.005), or greater than 6 months (OR 8.4, 95% CI 2.1-34.0, p=0.003).

Variables that decreased the odds of oral nutritive intake were cortical grey matter injury (OR 4.1, 95% CI 1.3-13.0, p=0.02), a hypoxia-ischemia CP etiology (OR 4.7, 95% CI 1.3-17.7,

p=0.02) and ICU stay between 1-3 months (OR 6.2, 95% CI 1.9-20.5, p=0.003), 4-6 months (OR 17.0, 95% CI 3.2-89.5, p=0.001), or greater than 6 months (OR 32.1, 95% CI 5.6-183.5, p<0.0005).

Variables that decreased the odds of understandable speech production were cortical grey matter injury (OR 8.5, 95% CI 2.7-26.8, p<0.0005), cerebral malformations (OR 6.9, 95% CI 2.3-20.9, p=0.001), intraventricular hemorrhage (OR 4.5, 95% CI 1.6-12.2, p=0.0004), periventricular leukomalacia (OR 3.3, 95% CI 1.4-7.9, p=0.006), an infection etiology (OR 25.6, 95% CI 2.5-259.9, p=0.006), a genetic etiology (OR 7.5, 95% CI 2.2-25.8, p=0.001), or ICU stay greater than 6 months (OR 6.6, 95% CI 1.4-31.1, p=0.02) (Table 14).

Discussion

We comprehensively captured caregiver and clinician-entered data on 97% of people with CP seen in a tertiary care CP Center and used this data to determine variables affecting the odds of walking, oral feeding, and speech. By sharing our methodology, we aim to facilitate replication of this dataset at other sites (https://bit.ly/CP-Intake-Methodology).

Racial disparities

Non-White people were likely under-represented in our data. Per US Census data, 43.8%, 75.8%, and 58.3% of residents identify as White in St. Louis City,³¹ Missouri,³² and Illinois,³³ respectively, compared to 83.1% of caregivers and 78.5% of people with CP identifying as White in our data. This is particularly notable given the established higher prevalence of CP in Black children in the US.¹ Our data highlights our Center's need to address racial inequities and the ongoing disparities in CP-related data globally.^{34,35}

Comparison to existing datasets

Compared to population-based GMFCS data from Australia³⁶, Northern Europe³⁷, Canada³⁸, and the US³⁹ (34-46% Level I, 13-17% Level V) the GMFCS distribution in our data set (15.8% Level I, 23.4% Level V) skewed toward greater gross motor functional limitations. In contrast, the CPRN registry, which primarily aggregates data from tertiary care sites in the US, reports a GMFCS distribution more like ours (20.6% at Level I, 25.5% at Level V).⁴⁰ Therefore, our data set may not be generalizable to population-based estimates, but may be generalizable to how people with CP present at tertiary care centers.

There is less population-based data on other functional classification systems, including none, to our knowledge, from the US. Population-based MACS data from Australia⁴¹, Northern Europe ³⁷, and Canada⁴² (72%-77% at Levels I-III) largely match our MACS distribution (77.7% at Levels I-III).

There has been a growing recognition of mixed motor phenotypes in CP, particularly given variability in CP classification using predominant tone type alone.^{43,44} A single center data set from Australia⁴⁵ showed that 55.2% of people with CP had multiple movement disorders, comparable to our data (59.6%). Descriptions of all tone types present in a person with CP may better describe how CP typically manifests, as opposed to classification using predominant tone type alone.⁴⁶

Rates of epilepsy in people with CP in Australia (37.2%⁴¹) are comparable to the 42.3% of people in our data set who are on anti-seizure medications. Single center data from Australia suggest that 64% (147/230) of people with CP and epilepsy have drug resistant epilepsy, which differs from our estimate of 31.0% (83/268 people on anti-seizure medications who are on at least 2 anti-seizure medications and had a seizure within the last 30 days). This difference may be due ascertainment bias between the two centers or variable definitions of drug resistant

epilepsy (the Australian cohort specified "ongoing seizures"⁴¹ vs. our specification of a seizure within the last 30 days).

Comparable to recent estimates that 8-30% of people with CP have contributing genetic etiologies, ^{29,47,48} 23% of people in our data set had a contributing genetic etiology. Population-based registries vary regarding which genetic conditions should be excluded, regardless of the phenotype.^{5,49} However, given recent affirmations that CP is a phenotypic diagnosis independent of its brain-related etiology, ^{24–26,48,50,51} registries may increasingly capture genetic data on people with CP. While this is ongoing, single center data sets can help illuminate genetic contributors to CP.^{47,52}

Variables affecting functional abilities after 5 years old

The relationship between initial ICU stay duration and post-discharge outcomes has been assessed prospectively using ICU cohorts,^{53,54} but with limited data on those with CP or on outcomes after age 2 (limiting assessments of walking, feeding, and speech). In our data, perhaps the best predictor of all assessed functional abilities after age 5 was the duration of the initial ICU stay.

Cortical grey matter injury and basal ganglia and thalamic injury have been implicated in motor developmental outcomes,^{55–57} findings which we re-demonstrated here. There is less data on functional outcomes for people with CP and brain malformations, which we demonstrate affect the odds of independent walking and understandable speech. Etiology also affected the odds of all assessed functional outcomes after age 5, again with little available data in the literature for comparison.

Future Work

In addition to further analyzing this data set (e.g. differences between people with and without genetic CP etiologies), we should investigate this methodology's effect on workflow (e.g. length of clinic visits) and medical care (e.g. rates of sleep evaluation and treatment). By sharing our methodology (<u>https://bit.ly/CP-Intake-Methodology</u>), we hope to collaboratively facilitate answering these questions and grow our understanding of how CP manifests.

References

- Van Naarden Braun K, Doernberg N, Schieve L, Christensen D, Goodman A, Yeargin-Allsopp M. Birth Prevalence of Cerebral Palsy: A Population-Based Study. *Pediatrics*. 2016;137(1):1-9. doi:10.1542/peds.2015-2872
- Hurvitz EA, Gross PH, Gannotti ME, Bailes AF, Horn SD. Registry-based Research in Cerebral Palsy: The Cerebral Palsy Research Network. *Phys Med Rehabil Clin N Am*. 2020;31(1):185-194. doi:10.1016/j.pmr.2019.09.005
- 3. Registry Sites | Cerebral Palsy Research Network. Accessed July 15, 2024. https://cprn.org/research/cerebral-palsy-registry-sites/
- 4. CPRN Document Download | Cerebral Palsy Research Network. Accessed July 15, 2024. https://cprn.org/cprn-document-download/?doc=/data-submission/CPRN-Data-Submission-Specification-v2dot2dot3.pdf&docname=Data%20Submission%20Specification
- 5. Goldsmith S, Smithers-Sheedy H, Almasri N, et al. Cerebral palsy registers around the world: A survey. *Dev Med Child Neurol*. 2024;66(6):765-777. doi:10.1111/DMCN.15798
- 6. Noritz G, Davidson L, Steingass K. Providing a Primary Care Medical Home for Children and Youth With Cerebral Palsy. *Pediatrics*. 2022;150(6). doi:10.1542/PEDS.2022-060055
- Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. In: *Pediatrics*. Vol 111. American Academy of Pediatrics; 2003:e89-e97. doi:10.1542/peds.111.1.e89
- 8. Sanger TD, Chen D, Delgado MR, et al. Definition and Classification of Negative Motor Signs in Childhood. *Pediatrics*. 2006;118(5):2159-2167. doi:10.1542/peds.2005-3016
- 9. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. *Movement Disorders*. 2010;25(11):1538-1549. doi:10.1002/mds.23088
- 10. Jaleel F, Rust A, Cheung S, et al. Caregiver descriptions of dystonia in cerebral palsy. *Ann Clin Transl Neurol*. 2024;11(2):242-250. doi:10.1002/ACN3.51941

- 11. Aravamuthan BR, Ueda K, Miao H, Gilbert L, Smith SE, Pearson TS. Gait features of dystonia in cerebral palsy. *Dev Med Child Neurol*. 2021;63(6):748-754. doi:10.1111/DMCN.14802
- 12. Aravamuthan BR, Pearson TS, Ueda K, et al. Determinants of gait dystonia severity in cerebral palsy. *Dev Med Child Neurol*. 2023;65(7):968-977. doi:10.1111/DMCN.15524
- 13. Gilbert LA, Gandham S, Ueda K, Chintalapati K, Pearson T, Aravamuthan BR. Upper Extremity Dystonia Features in People With Spastic Cerebral Palsy. *Neurol Clin Pract*. 2023;13(6). doi:10.1212/CPJ.000000000200207
- Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the Hypertonia Assessment Tool (HAT): A discriminative tool for hypertonia in children. *Dev Med Child Neurol*. 2010;52(5). doi:10.1111/j.1469-8749.2009.03483.x
- Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. *Dev Med Child Neurol*. 1997;39(4):214-223. doi:10.1111/j.1469-8749.1997.tb07414.x
- 16. CanChild. Accessed July 29, 2024. https://canchild.ca/en/resources/42-gross-motor-functionclassification-system-expanded-revised-gmfcs-e-r
- 17. Eliasson AC, Krumlinde-Sundholm L, Rösblad B, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: Scale development and evidence of validity and reliability. *Dev Med Child Neurol*. 2006;48(7):549-554. doi:10.1017/S0012162206001162
- Hidecker MJC, Paneth N, Rosenbaum PL, et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. *Dev Med Child Neurol*. 2011;53(8):704-710. doi:10.1111/j.1469-8749.2011.03996.x
- 19. Pennington L, Virella D, Mjøen T, et al. Development of The Viking Speech Scale to classify the speech of children with cerebral palsy. *Res Dev Disabil*. 2013;34(10):3202-3210. doi:10.1016/J.RIDD.2013.06.035

- Baranello G, Signorini S, Tinelli F, et al. Visual Function Classification System for children with cerebral palsy: development and validation. *Dev Med Child Neurol*. Published online January 1, 2019. doi:10.1111/dmcn.14270
- Sellers D, Mandy A, Pennington L, Hankins M, Morris C. Development and reliability of a system to classify the eating and drinking ability of people with cerebral palsy. *Dev Med Child Neurol*. 2014;56(3):245-251. doi:10.1111/dmcn.12352
- Himmelmann K, Horber V, De La Cruz J, et al. MRI classification system (MRICS) for children with cerebral palsy: development, reliability, and recommendations. *Dev Med Child Neurol*. 2017;59(1):57-64. doi:10.1111/dmcn.13166
- 23. NIH Common Data Elements (CDE) Repository. Accessed July 18, 2024. https://cde.nlm.nih.gov/home
- 24. Aravamuthan BR, Fehlings D, Shetty S, et al. Variability in Cerebral Palsy Diagnosis. *Pediatrics*. 2021;147(2):e2020010066. doi:10.1542/peds.2020-010066
- 25. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. *Dev Med Child Neurol Suppl.* 2007;109:8-14. Accessed March 26, 2019. http://www.ncbi.nlm.nih.gov/pubmed/17370477
- 26. Aravamuthan BR, Fehlings DL, Novak I, et al. Uncertainties regarding cerebral palsy diagnosis: opportunities to operationalize the consensus definition. *Neurol Clin Pract*. 2023;in press. doi:10.1101/2023.06.29.23292028
- 27. Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible The Neighborhood Atlas. *New England Journal of Medicine*. 2018;378(26):2456-2458. doi:10.1056/NEJMP1802313
- 28. Aravamuthan BR, Shusterman M, Green Snyder L, Lemmon ME, Bain JM, Gross P. Diagnostic preferences include discussion of etiology for adults with cerebral palsy and their caregivers. *Dev Med Child Neurol*. 2022;64(6):723-733. doi:10.1111/DMCN.15164

- Srivastava S, Lewis SA, Cohen JS, et al. Molecular Diagnostic Yield of Exome Sequencing and Chromosomal Microarray in Cerebral Palsy: A Systematic Review and Meta-analysis. *JAMA Neurol*. 2022;79(12):1287-1295. doi:10.1001/JAMANEUROL.2022.3549
- Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2010;51(6):1069-1077. doi:10.1111/J.1528-1167.2009.02397.X
- 31. Census Data | City of St. Louis. Accessed July 25, 2024. https://www.stlouismo.gov/government/departments/planning/research/census/data/index.cfm
- 32. Missouri Demographics Map of Population by Race Census Dots. Accessed July 25, 2024. https://www.censusdots.com/race/missouri-demographics
- 33. Illinois Demographics Map of Population by Race Census Dots. Accessed July 25, 2024. https://www.censusdots.com/race/illinois-demographics
- 34. McIntyre S, Goldsmith S, Webb A, et al. Global prevalence of cerebral palsy: A systematic analysis. *Dev Med Child Neurol*. Published online August 11, 2022. doi:10.1111/DMCN.15346
- 35. Avila-Soto F, Kakooza AM, Ueda K, Aravamuthan B. Studies of CP Prevalence: Disparities in Authorship, Citations, and Geographic Location. *Pediatr Neurol*. 2023;143:59-63. doi:10.1016/J.PEDIATRNEUROL.2023.02.003
- 36. Reid SM, Carlin JB, Reddihough DS. Using the Gross Motor Function Classification System to describe patterns of motor severity in cerebral palsy. *Dev Med Child Neurol*. 2011;53(11):1007-1012. doi:10.1111/J.1469-8749.2011.04044.X
- 37. Hollung SJ, Hägglund G, Gaston MS, et al. Point prevalence and motor function of children and adolescents with cerebral palsy in Scandinavia and Scotland: a CP-North study. *Dev Med Child Neurol*. 2021;63(6):721. doi:10.1111/DMCN.14764

- Huroy M, Behlim T, Andersen J, et al. Stability of the Gross Motor Function Classification System over time in children with cerebral palsy. *Dev Med Child Neurol*. 2022;64(12):1487-1493. doi:10.1111/DMCN.15375
- 39. Kirby RS, Wingate MS, Van Naarden Braun K, et al. Prevalence and functioning of children with cerebral palsy in four areas of the United States in 2006: a report from the Autism and Developmental Disabilities Monitoring Network. *Res Dev Disabil.* 2011;32(2):462-469. doi:10.1016/J.RIDD.2010.12.042
- 40. CPRN DCC Portal | Login. Accessed July 30, 2024. https://my.cprn.org
- 41. Feroze N, Karim T, Ostojic K, et al. Clinical features associated with epilepsy occurrence, resolution, and drug resistance in children with cerebral palsy: A population-based study. *Dev Med Child Neurol*. 2024;66(6):793-803. doi:10.1111/DMCN.15807
- 42. Springer A, Dyck Holzinger S, Andersen J, et al. Profile of children with cerebral palsy spectrum disorder and a normal MRI study. *Neurology*. 2019;93(1):E88-E96.
 doi:10.1212/WNL.000000000007726/ASSET/6B13CCA1-E6DD-4635-94D9-352A84BC8DFD/ASSETS/GRAPHIC/14TTU1A.JPEG
- 43. Gainsborough M, Surman G, Maestri G, Colver A, Cans C. Validity and reliability of the guidelines of the surveillance of cerebral palsy in Europe for the classification of cerebral palsy. *Dev Med Child Neurol.* 2008;50(11):828-831. doi:10.1111/J.1469-8749.2008.03141.X
- 44. Reid SM, Carlin JB, Reddihough DS. Distribution of motor types in cerebral palsy: how do registry data compare? *Dev Med Child Neurol*. 2011;53(3):233-238. doi:10.1111/J.1469-8749.2010.03844.X
- 45. Dar H, Stewart K, McIntyre S, Paget S. Multiple motor disorders in cerebral palsy. *Dev Med Child Neurol.* 2024;66(3):317-325. doi:10.1111/DMCN.15730
- 46. Christine C, Dolk H, Platt MJ, Colver A, Prasauskiene A, Krageloh-Mann I. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. *Dev Med Child Neurol Suppl*. 2007;109:35-38.

- 47. May HJ, Fasheun JA, Bain JM, et al. Genetic testing in individuals with cerebral palsy. *Dev Med Child Neurol*. Published online June 2021. doi:10.1111/dmcn.14948
- 48. Fahey MC, Maclennan AH, Kretzschmar D, Gecz J, Kruer MC. The genetic basis of cerebral palsy. *Dev Med Child Neurol*. 2017;59(5):462-469. doi:10.1111/dmcn.13363
- 49. Smithers-Sheedy H, Badawi N, Blair E, et al. What constitutes cerebral palsy in the twenty-first century? *Dev Med Child Neurol*. 2014;56(4):323-328. doi:10.1111/dmcn.12262
- 50. Aravamuthan BR, Shevell M, Kim YM, et al. Role of child neurologists and neurodevelopmentalists in the diagnosis of cerebral palsy: A survey study. *Neurology*. 2020;95(21):962-972. doi:10.1212/WNL.00000000011036
- 51. Aravamuthan BR, Shusterman M, Snyder LG, Lemmon ME, Bain JM, Gross PH. Diagnostic preferences amongst cerebral palsy community members: a cerebral palsy diagnosis should be accompanied by description of its etiology. *Dev Med Child Neurol*. Published online 2022.
- 52. Chopra M, Gable DL, Love-Nichols J, et al. Mendelian etiologies identified with whole exome sequencing in cerebral palsy. *Ann Clin Transl Neurol*. 2022;9(2):193-205. doi:10.1002/acn3.51506
- 53. Royer ASM, Busari JO. A systematic review of the impact of intensive care admissions on post discharge cognition in children. *Eur J Pediatr*. 2021;180(12):3443-3454. doi:10.1007/S00431-021-04145-5
- 54. Subedi D, Deboer MD, Scharf RJ. Developmental trajectories in children with prolonged NICU stays. *Arch Dis Child*. 2017;102(1):29-34. doi:10.1136/ARCHDISCHILD-2016-310777
- 55. Martinez-Biarge M, Diez-Sebastian J, Kapellou O, et al. Predicting motor outcome and death in term hypoxic-ischemic encephalopathy. *Neurology*. 2011;76(24):2055-2061. doi:10.1212/WNL.0b013e31821f442d
- 56. Kidokoro H, Anderson PJ, Doyle LW, Woodward LJ, Neil JJ, Inder TE. Brain injury and altered brain growth in preterm infants: predictors and prognosis. *Pediatrics*. 2014;134(2). doi:10.1542/PEDS.2013-2336

57. Anderson PJ, Cheong JLY, Thompson DK. The predictive validity of neonatal MRI for neurodevelopmental outcome in very preterm children. *Semin Perinatol*. 2015;39(2):147-158. doi:10.1053/J.SEMPERI.2015.01.008




Figure 1. Geographical distribution of people with CP represented in this data set.

Table 1. Demographics of people with C	<u>P (caregiv</u>	ver-entered)	
	Me	eans, 95% CI	or
	n, %	6 (Total N=6	33)
Age (Mean, 95% CI)	9.1	, 8.3 -	- 9.9
Missing (n)	0	, 0.0%	
Gender (n)			
Male	337	, 53.4%	
Female	292	, 46.3%	
Other	0	, 0.0%	
Prefer not to say	2	, 0.3%	
Missing	2	, 0.3%	
Race, caregiver (n)			
White	523	, 83.1%	
Black	82	, 13.0%	
American Indian or Alaska Native	8	, 1.3%	
Asian	7	, 1.1%	
Native Hawaiian/Pacific Islander	2	, 0.3%	
Other	12	, 1.9%	
Prefer not to say / Don't know	13	, 2.1%	
Missing	4	, 0.6%	
Race, person with CP (n)		,	
White	492	, 78.5%	
Black	113	, 18.0%	
American Indian or Alaska Native	8	, 1.3%	
Asian	12	, 1.9%	
Native Hawaiian/Pacific Islander	2	, 0.3%	
Other	12	, 1.9%	
Prefer not to say / Don't know	24	, 3.8%	
Missing	6	, 0.9%	
Highest education, caregiver		,	
No high school	41	, 6.7%	
High school diploma / GED	317	, 51.6%	
Bachelor's degree	123	, 20.0%	
Post-graduate degree	128	, 20.8%	
Prefer not to say / Don't know	5	, 0.8%	
Missing	19	, 3.0%	
Area deprivation index (Mean, 95% CI)*	63.4	<u>, 59.8</u>	- 67.0
Less than 25% ile	39	, 6.2%	07.0
25 to less than 50% ile	138	, 21.8%	
50 to less than 75% ile	223	, 35.2%	
75% ile or greater	233	, 36.8%	
Missing (n)	0	, 0.0%	
Distance from center (Mean, 95% CI)	68.128	, <u>58.47</u>	- 77.79
Less than 50 miles (n)	324	, 51.2%	/ >
50-100 miles (n)	128	, 20.2%	
50 100 miles (ii)	120	, 20.270	

Table 1. Demographics of people with CP (caregiver-entered)

Greater than 100 miles (n)	181	,	28.6%	
Missing (n)	0	,	0.0%	

*Area deprivation index was calculated from the 9-digit zip codes in the electronic health record. Missing data percentages are calculated with a denominator of N=633. Other percentages are calculated with a denominator of 633 - n of missing data.

Predominant tone/					Other	tone	e / mov	emen	t (n, %	*)					
movement															
(n)	Spasticity	Dystonia	Нуро	tonia	Chor	ea	Athet	tosis	Ata	xia	Oth	er	No	ne	TOT
Spasticity		257, 40.7%	142,	22.5%	1, (0.2%	1,	0.2%	3,	0.5%	2,	0.3%	118,	18.7%	429, 6
Dystonia	57, 9.0%		51,	8.1%	4, (0.6%	3,	0.5%	2,	0.3%	1,	0.2%	1,	0.2%	72, 1
Hypotonia	44, 7.0%	34, 5.4%			6, (0.9%	1,	0.2%	2,	0.3%	5,	0.8%	49,	7.8%	120, 1
Chorea	0, 0.0%	4, 0.6%	5,	0.8%			0,	0.0%	0,	0.0%	0,	0.0%	1,	0.2%	6,
Athetosis	1, 0.2%	1, 0.2%	0,	0.0%	0, (0.0%			0,	0.0%	0,	0.0%	0,	0.0%	1,
Ataxia	2, 0.3%	1, 0.2%	2,	0.3%	0, (0.0%	0,	0.0%			0,	0.0%	1,	0.2%	4,
Other	0, 0.0%	0, 0.0%	0,	0.0%	0, (0.0%	0,	0.0%	0,	0.0%	0,	0.0%	0,	0.0%	0,
TOTAL	104, 16.5%	297, 47.0%	200,	31.6%	11, 1	1.7%	5,	0.8%	7,	1.1%	8,	1.3%	170,	26.9%	

Table 2. Tone and movement conditions (clinician-entered)

*There was 1 missing data entry out of a Total N of 633 (denominator for all % is 632)

Table 3. Distribution of tone and movement conditions (clinician-entered)

	n, %
	(Total N=633)
Diplegia	121 , 19.7%
Quadriplegia	288 , 47.0%
Right monoplegia	3 , 0.5%
Right hemiplegia	56 , 9.1%
Right triplegia	28 , 4.6%
Left monoplegia	5 , 0.8%
Left hemiplegia	82 , 13.4%
Left triplegia	30 , 4.9%
Missing	20 , 3.2%

I100, 15.8%II194, 30.6%III74, 11.7%IV117, 18.5%V148, 23.4%Macsing0, 0.0%MACS (n, %) (Age 4+, N=516)	Table 4. Functional abilities (clinician	i-entered)	
II194, 30.6%III74, 11.7%IV117, 18.5%V148, 23.4%Missing0, 0.0%MACS (n, %) (Age 4+, N=516)-I130, 27.8%II187, 40.0%III50, 10.7%V42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570)-I288, 55.9%II76, 14.8%III24, 4.7%V36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)-I284, 50.4%III139, 24.6%III76, 13.5%VFCS (n, %) (Age 2+, N=594)-I194, 36.0%III50, 9.3%CFCS (n, %) (Age 2+, N=594)-I194, 36.0%III50, 9.3%VSS (n, %) (Age 4+, N=516)-I139, 29.8%VSS (n, %) (Age 4+, N=516)-II110, 23.6%VI11110, 23.6%VI111110, 23.6%VSS (n, %) (Age 4+, N=516)-II143, 30.6%Viscing409.5%	GMFCS (n,%) (Age 0+, N=633)			
III 74 , 11.7%IV117, 18.5%V148, 23.4%Missing0, 0.0%MACS (n, %) (Age 4+, N=516)1I130, 27.8%II187, 40.0%III50, 10.7%V42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570) $$	Ι	100	,	15.8%
IV117, 18.5%V148, 23.4%Missing0, 0.0%MACS (n, %) (Age 4+, N=516)1130, 27.8%II187, 40.0%III50, 10.7%V42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570)1I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)-I284, 50.4%III139, 24.6%III139, 24.6%III76, 13.5%VFCS (n, %) (Age 2+, N=594)-I194, 36.0%CFCS (n, %) (Age 2+, N=594)-I194, 36.0%III50, 9.3%CFCS (n, %) (Age 4+, N=516)-VSS (n, %) (Age 4+, N=516)-I139, 29.8%III110, 23.6%VSS (n, %) (Age 4+, N=516)-II143, 30.6%III75, 16.1%IV143, 30.6%III75, 16.1%IV143, 30.6%	II	194	,	30.6%
V148, 23.4% MissingMissing0, 0.0%MACS (n, %) (Age 4+, N=516) 1 I130, 27.8%II187, 40.0%III50, 10.7%IV42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570) 2 I288, 55.9%III76, 14.8%III24, 4.7%V36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625) $-$ I284, 50.4%III139, 24.6%III139, 24.6%III139, 24.6%III139, 24.6%Missing61, 9.8%CFCS (n, %) (Age 1+, N=625) $-$ V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594) $-$ I194, 36.0%V109, 20.2%V98, 18.2%Missing55, 9.3%VSS (n, %) (Age 4+, N=516) $-$ II110, 23.6%III110, 23.6%III110, 23.6%III110, 23.6%III110, 23.6%III110, 23.6%III110, 23.6%III110, 29.8%III100, 29.8%	III	74	,	11.7%
Missing00.0%MACS (n, %) (Age 4+, N=516)1I130, 27.8%II187, 40.0%III50, 10.7%V42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570)1I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)1I284, 50.4%III139, 24.6%IIII76, 13.5%VFCS (n, %) (Age 1+, N=625)1CFCS (n, %) (Age 2+, N=594)1I194, 36.0%III50, 9.3%CFCS (n, %) (Age 2+, N=594)1I194, 36.0%III50, 9.3%VSS (n, %) (Age 4+, N=516)1VSS (n, %) (Age 4+, N=516)1II109, 20.2%VSS (n, %) (Age 4+, N=516)1III75, 16.1%III75, 16.1%III <t< td=""><td>IV</td><td>117</td><td>,</td><td>18.5%</td></t<>	IV	117	,	18.5%
MACS (n, %) (Age 4+, N=516)I130, 27.8%II187, 40.0%III50, 10.7%IV42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570)I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)II284, 50.4%III139, 24.6%III76, 13.5%VFCS (n, %) (Age 1+, N=625)II284, 50.4%III76, 13.5%CFCS (n, %) (Age 2+, N=594)II194, 36.0%III50, 9.3%CFCS (n, %) (Age 2+, N=594)II194, 36.0%III50, 9.3%VSS (n, %) (Age 4+, N=516)IVSS (n, %) (Age 4+, N=516)III75, 16.1%III75, 16.1%III75, 16.1%IIII75, 16.1%IIII75, 16.1%IV143, 30.6%	V	148	,	23.4%
I13027.8%II187, 40.0%III50, 10.7%IV42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570)1I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)1I139, 24.6%III76, 13.5%IV39, 6.9%VFCS (n, %) (Age 1+, N=625)26I194, 36.0%III76, 9.3%CFCS (n, %) (Age 2+, N=594)1I194, 36.0%III50, 9.3%VSS (n, %) (Age 4+, N=516)1VSS (n, %) (Age 4+, N=516)1II139, 29.8%III75, 16.1%III75, 16.1%IV143, 30.6%Missing65, 95%	Missing	0	,	0.0%
II 187 , 40.0%III50, 10.7%IV42, 9.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570)	MACS (n, %) (Age 4+, N=516)			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	I	130	,	27.8%
IV429.0%V59, 12.6%Missing48, 9.3%EDACS (n, %) (Age 3+, N=570) 1 I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625) 2 I284, 50.4%III139, 24.6%IV39, 6.9%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594) 1 I194, 36.0%III50, 9.3%CFCS (n, %) (Age 2+, N=594) 1 I194, 36.0%III50, 9.3%VSS (n, %) (Age 4+, N=516) 1 VSS (n, %) (Age 4+, N=516) 1 II75, 16.1%III75, 16.1%IV143, 30.6%	II	187	,	40.0%
V59,12.6%Missing48,9.3%EDACS (n, %) (Age 3+, N=570)	III	50	,	10.7%
Missing489.3%EDACS (n, %) (Age 3+, N=570)11288, 55.9%1176, 14.8%11124, 4.7%11224, 4.7%11324, 7.0%11124, 7.0%11124, 7.0%111284, 50.4%111139, 24.6%111139, 24.6%111139, 24.6%11176, 13.5%11176, 13.5%11176, 13.5%11176, 13.5%11176, 13.5%11176, 36.0%11176, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%11150, 9.3%1139, 29.8%111110, 23.6%11175, 16.1%11175, 16.1%11175, 16.1%11175, 16.1%11174, 30.6%	IV	42	,	9.0%
EDACS (n, %) (Age 3+, N=570)I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)V284, 50.4%II139, 24.6%III139, 24.6%III76, 13.5%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594)I194, 36.0%II88, 16.3%III50, 9.3%VSS (n, %) (Age 4+, N=516)VSS (n, %) (Age 4+, N=516)II139, 29.8%II110, 23.6%III75, 16.1%IV143, 30.6%Missing409.5%	V	59	,	12.6%
EDACS (n, %) (Age 3+, N=570)I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)V284, 50.4%II139, 24.6%III139, 24.6%III76, 13.5%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594)I194, 36.0%II88, 16.3%III50, 9.3%VSS (n, %) (Age 4+, N=516)VSS (n, %) (Age 4+, N=516)II139, 29.8%II110, 23.6%III75, 16.1%IV143, 30.6%Missing409.5%	Missing	48	,	
I288, 55.9%II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)II284, 50.4%II139, 24.6%III76, 13.5%IV39, 6.9%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594)II194, 36.0%III50, 9.3%IV109, 20.2%V98, 18.2%Missing55, 9.3%VSS (n, %) (Age 4+, N=516)II139, 29.8%III110, 23.6%III75, 16.1%IV143, 30.6%Missing400.5%				
II76, 14.8%III24, 4.7%IV36, 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)I284, 50.4%II139, 24.6%III76, 13.5%V39, 6.9%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594)I194, 36.0%II88, 16.3%IV109, 20.2%V98, 18.2%Missing55, 9.3%VSS (n, %) (Age 4+, N=516)I139, 29.8%II110, 23.6%III75, 16.1%IV143, 30.6%Missing400.5%		288	,	55.9%
III 24 4.7% IV 36 , 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)1I 284 , 50.4%III139, 24.6%III139, 24.6%III76, 13.5%IV39, 6.9%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594)1I194, 36.0%III50, 9.3%IV109, 20.2%V98, 18.2%Missing55, 9.3%VSS (n, %) (Age 4+, N=516)1I139, 29.8%III75, 16.1%IV143, 30.6%Missing409.5%	II		,	
IV 36 7.0%V91, 17.7%Missing55, 9.6%VFCS (n, %) (Age 1+, N=625)1I284, 50.4%II139, 24.6%III76, 13.5%IV39, 6.9%V26, 4.6%Missing61, 9.8%CFCS (n, %) (Age 2+, N=594) $$	III	24	,	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	IV	36	•	
Missing 55 , 9.6% VFCS (n, %) (Age 1+, N=625)I 284 , 50.4% II139, 24.6% III76, 13.5% IV39, 6.9% V26, 4.6% Missing61, 9.8% CFCS (n, %) (Age 2+, N=594)I194,I194, 36.0% II88, 16.3% III50, 9.3% IV109, 20.2% V98, 18.2% Missing55, 9.3% VSS (n, %) (Age 4+, N=516)I139,II110, 23.6% III75, 16.1% IV143, 30.6% Missing40 9.5%	V		,	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Missing	55	,	
I 284 , 50.4% II 139 , 24.6% III 76 , 13.5% IV 39 , 6.9% V 26 , 4.6% Missing 61 , 9.8% CFCS (n, %) (Age 2+, N=594)I 194 I 194 , 36.0% III 88 , 16.3% III 50 , 9.3% IV 109 , 20.2% V 98 , 18.2% Missing 55 , 9.3% VSS (n, %) (Age 4+, N=516)I 139 II 110 , 23.6% III 75 , 16.1% IV 143 , 30.6% Missing 40 0.5%	5		,	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		284	,	50.4%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	II		,	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	III		,	
$\begin{array}{c cccc} V & 26 & , & 4.6\% \\ \hline Missing & 61 & , & 9.8\% \\ \hline CFCS (n, \%) (Age 2+, N=594) \\ \hline & I & 194 & , & 36.0\% \\ \hline II & 88 & , & 16.3\% \\ \hline III & 88 & , & 16.3\% \\ \hline III & 50 & , & 9.3\% \\ \hline IV & 109 & , & 20.2\% \\ \hline V & 98 & , & 18.2\% \\ \hline VSS (n, \%) (Age 4+, N=516) \\ \hline & I & 139 & , & 29.8\% \\ \hline II & 110 & , & 23.6\% \\ \hline III & 75 & , & 16.1\% \\ \hline IV & 143 & , & 30.6\% \\ \hline Missing & 40 & 0.5\% \\ \hline \end{array}$	IV		,	
Missing 61 , 9.8% CFCS (n, %) (Age 2+, N=594)I 194 , 36.0% II88, 16.3% III50, 9.3% IV109, 20.2% V98, 18.2% Missing55, 9.3% VSS (n, %) (Age 4+, N=516)I139,II110, 23.6% III75, 16.1% IV143, 30.6%			,	
$\begin{array}{c c} CFCS (n, \%) (Age 2+, N=594) \\ \hline I & 194 & , 36.0\% \\ II & 88 & , 16.3\% \\ III & 50 & , 9.3\% \\ IV & 109 & , 20.2\% \\ V & 98 & , 18.2\% \\ \hline V & 98 & , 18.2\% \\ \hline Missing & 55 & , 9.3\% \\ \hline VSS (n, \%) (Age 4+, N=516) \\ \hline I & 139 & , 29.8\% \\ II & 110 & , 23.6\% \\ \hline III & 75 & , 16.1\% \\ \hline IV & 143 & , 30.6\% \\ \hline Missing & 40 & 0.5\% \\ \end{array}$	Missing			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	e		,	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		194	•	36.0%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$,	
IV 109 , 20.2% V 98 , 18.2% Missing 55 , 9.3% VSS (n, %) (Age 4+, N=516)			,	
V 98 , 18.2% Missing 55 , 9.3% VSS (n, %) (Age 4+, N=516)			,	
Missing 55 9.3% VSS (n, %) (Age 4+, N=516) I 139 , 29.8% II 110 , 23.6% III 110 , 23.6% III 175 , 16.1% IV 143 , 30.6% Missing 40 9.5% 9.5% 10.5%			,	
VSS (n, %) (Age 4+, N=516) I 139 , 29.8% II 110 , 23.6% III 75 , 16.1% IV 143 , 30.6%			,	
I 139 , 29.8% II 110 , 23.6% III 75 , 16.1% IV 143 , 30.6% Missing 40 0.5%		20	,	2.070
II 110 23.6% III 75 , 16.1% IV 143 , 30.6% Missing 40 0.5%		139		29.8%
III 75 , 16.1% IV 143 , 30.6% Missing 40 0.5%			,	
IV 143 , 30.6%			,	
Missing 40 0.5%			,	
	Missing	49	,	9.5%

Table 4. Functional abilities (clinician-entered)

GMFCS – Gross motor function classification system, MACS – Manual ability classification system, EDACS – Eating and drinking ability classification system, VFCS – Visual function classification system, CFCS – Communication function classification system, VSS – Viking speech scale. Missing data percentages are calculated with a denominator of N=633. Other percentages are calculated with a denominator of 633 – n of missing data.

n, % (Total N=633)MRICS (n) 59 , 9.5%White matter injury - any 323323, 52.3%White matter injury - PVL161, 26.1%White matter injury - PVL161, 26.1%White matter injury - IVH96, 15.5%White matter injury - Other111, 18.0%Grey matter injury - Other111, 18.0%Grey matter injury - Basal ganglia/ Thalamus43, 7.0%Grey matter injury - Arterial distribution Infarction38, 6.1%Grey matter injury - Watershed7, 1.1%Grey matter injury - Cortical Other79, 12.8%Malformation/Maldevelopment92, 14.9%MRI images unavailable/not done82, 13.3%Etiology (n)	b. Drain with patients and chology	(ennie	/iui	i chicicu
MRICS (n)Normal 59 , 9.5% White matter injury - any 323 , 52.3% White matter injury - PVL 161 , 26.1% White matter injury - IVH 96 , 15.5% White matter injury - Other 111 , 18.0% Grey matter injury - Basal ganglia/ Thalamus 43 , 7.0% Grey matter injury - Arterial distribution Infarction 38 , 6.1% Grey matter injury - Watershed7, 1.1% Grey matter injury - Cortical Other 79 , 12.8% Malformation/Maldevelopment 92 , 14.9% MRI images unavailable/not done 82 , 13.3% Etiology (n) 2.4%		ļ	,	
Normal 59 , 9.5% White matter injury - any 323 , 52.3% White matter injury - PVL 161 , 26.1% White matter injury - IVH 96 , 15.5% White matter injury - Other 111 , 18.0% Grey matter injury - any 146 , 23.6 Grey matter injury - Basal ganglia/ Thalamus 43 , 7.0% Grey matter injury - Arterial distribution Infarction 38 , 6.1% Grey matter injury - Watershed7, 1.1% Grey matter injury - Watershed7, 1.1% Malformation/Maldevelopment 92 , 14.9% MRI images unavailable/not done 82 , 13.3% Etiology (n) 2.4%		(Tot	al I	N=633)
White matter injury - any 323 , 52.3% White matter injury - PVL161, 26.1% White matter injury - IVH96, 15.5% White matter injury - Other111, 18.0% Grey matter injury - any146, 23.6 Grey matter injury - Basal ganglia/ Thalamus43, 7.0% Grey matter injury - Arterial distribution Infarction38, 6.1% Grey matter injury - Watershed7, 1.1% Grey matter injury - Watershed7, 1.1% Malformation/Maldevelopment92, 14.9% MRI images unavailable/not done82, 13.3% Etiology (n)				
White matter injury - PVL161,26.1%White matter injury - IVH96,15.5%White matter injury - Other111,18.0%Grey matter injury - Other111,18.0%Grey matter injury - Basal ganglia/ Thalamus43,7.0%Grey matter injury - Arterial distribution Infarction38,6.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Vatershed7,1.1%Grey matter injury - Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)2.4%			,	
White matter injury - IVH96,15.5%White matter injury - Other111,18.0%Grey matter injury - any146,23.6Grey matter injury - Basal ganglia/ Thalamus43,7.0%Grey matter injury - Arterial distribution Infarction38,6.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)2.4%	White matter injury - any	323	,	52.3%
White matter injury - Other111,18.0%Grey matter injury - any146,23.6Grey matter injury - Basal ganglia/ Thalamus43,7.0%Grey matter injury - Arterial distribution Infarction38,6.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)2.4%	White matter injury - PVL	161	,	26.1%
Grey matter injury - any ganglia/ Thalamus146,23.6Grey matter injury - Basal ganglia/ Thalamus43,7.0%Grey matter injury - Arterial distribution Infarction38,6.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Watershed7,1.1%Grey matter injury - Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)	White matter injury - IVH	96	,	15.5%
Grey matter injury – Basal ganglia/ Thalamus437.0%Grey matter injury – Arterial distribution Infarction38,6.1%Grey matter injury – Watershed7,1.1%Grey matter injury – Watershed7,1.1%Grey matter injury – Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)2.4%	White matter injury - Other	111	,	18.0%
ganglia/ Thalamus437.0%Grey matter injury – Arterial distribution Infarction38,Grey matter injury – Watershed7,1.1%Grey matter injury – Watershed7,1.1%Grey matter injury – Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)	Grey matter injury - any	146	,	23.6
distribution Infarction58,6.1%Grey matter injury – Watershed7,1.1%Grey matter injury – Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Etiology (n)2.4%	• • • •	43	,	7.0%
Grey matter injury - Cortical Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Missing15,2.4%		38	,	6.1%
Other79,12.8%Malformation/Maldevelopment92,14.9%MRI images unavailable/not done82,13.3%Missing15,2.4%Etiology (n)	Grey matter injury – Watershed	7	,	1.1%
MRI images unavailable/not done 82 , 13.3% Missing 15 , 2.4% Etiology (n)		79	,	12.8%
MRI images unavailable/not done 82 , 13.3% Missing 15 , 2.4% Etiology (n)	Malformation/Maldevelopment	92	,	14.9%
Etiology (n)	MRI images unavailable/not	82	,	13.3%
Etiology (n)	Missing	15	,	2.4%
	Etiology (n)			
Infection 34, 5.4%	Infection	34	,	5.4%
Prematurity 251 , 39.7%	Prematurity	251	,	39.7%
Stroke 82 , 13.0%	Stroke	82	,	13.0%
Trauma 20 , 3.2%	Trauma	20	,	3.2%
Hypoxia-ischemia 80 , 12.6%		80	,	12.6%
Genetic/Metabolic 146 , 23.1%	¥ 1	146	,	23.1%
Unknown 58 , 9.2%	Unknown	58	,	9.2%
Other 40 , 6.3%	Other	40	,	6.3%
Missing 0 , 0.0%	Missing	0	,	0.0%

Table 5. Brain MRI patterns and etiology (clinician-entered)

MRICS – MRI Classification System, PVL – periventricular leukomalacia, IVH – intraventricular hemorrhage. Missing data percentages are calculated with a denominator of N=633. Other percentages are calculated with a denominator of 633 – n of missing data.

Means, 95% CI or
n, % (Total N=633)
34.9 , 34.0 - 35.9
322 , 52.8%
75 , 12.3%
35 , 5.7%
56 , 9.2%
122 , 20.0%
23 , 3.6%
315 , 51.6%
295 , 48.4%
23 , 3.6%
167 , 28.6%
121 , 20.7%
272 , 46.6%
24 , 4.1%
49 , 7.7%
149 , 24.1%
179 , 28.9%
180 , 29.1%
63 , 10.2%
35 , 5.7%
13 , 2.1%
14 , 2.2%

Table 6. Birth details (caregiver-entered)

Tuble 7. Wotor medication and injectuor		n, (-
Motor medications (n)	(100	u r	-033)
Baclofen	221		34.9%
Gabapentin	154	,	24.3%
Diazepam	144	,	22.7%
Clonidine	121	,	19.1%
Levodopa	55	,	8.7%
Trihexyphenidyl	31	,	4.9%
Other	17	,	2.7%
None indicated	275		43.4%
Botulinum toxin (n)		,	
Have had injections	333	,	52.6%
Missing	0	,	0.0%
Injection location			
Upper Arms	98	,	15.7%
Lowers Arms	97	,	15.6%
Hands	50	,	8.0%
Upper Legs	190	,	30.5%
Lower Legs	248	,	39.8%
Feet	27	,	4.3%
Neck	13	,	2.1%
Salivary Glands	25	,	4.0%
Missing	10	,	1.6%
Injection last received			
Less than 3 months ago	115	,	18.4%
3-6 months ago	63	,	10.1%
6-12 months ago	26	,	4.2%
More than 1 year ago	121	,	19.4%
Missing	8	,	1.3%
Duration injections have been recei	ved		
Less than 1 year	45	,	7.3%
1-2 years	47	,	7.6%
More than 2 years	96	,	15.6%
Missing	16	,	7.8%

Table 7. Motor medication and injectables history (caregiver-entered)

Table 8. Orthotics and equipment (care	giver-entered)
	n, %
	(Total N=633)
Orthotics (n)	
Left Ankle-foot orthosis	404 , 63.8%
Right Ankle-foot orthosis	404 , 63.8%
Left Supra-malleolar orthosis	82 , 13.0%
Right Supra-malleolar orthosis	74 , 11.7%
Left hand splint	130 , 20.5%
Right hand splint	125 , 19.7%
Left knee immobilizer	66 , 10.4%
Right knee immobilizer	72 , 11.4%
Left stretching split	90 , 14.2%
Right stretching splint	96 , 15.2%
Left shoe insert	88 , 13.9%
Right shoe insert	93 , 14.7%
Trunk support vest	124 , 19.6%
None indicated	57 , 9.0%
Equipment (n)	
Communication Device / Picture	
Board	132 , 20.9%
Manual Wheelchair	258 , 40.8%
Motorized Wheelchair	33 , 5.2%
Adaptive Stroller	133 , 21.0%
Stander - Less than 5 hours a week	91 , 14.4%
Stander - 5-9 hours a week	75 , 11.8%
Stander - 10 hours or more a week	26 , 4.1%
Stander - usage unspecified	5 , 0.8%
Gait trainer	117 , 18.5%
Walker	94 , 14.8%
Feeding Chair	65 , 10.3%
Bath Chair	206 , 32.5%
Lift (e.g. Hoyer)	33 , 5.2%
None indicated	173 , 27.3%
Missing data percentages are calculated	,

T 11 0	0.1.	1	•	· · · · · · · · · · · · · · · · · · ·
Table X	()rthotics	and	equinment	(caregiver-entered)
rable 0.	Ormones	anu	equipment	(calegiver-entered)

Table 9. Therapies and schooling (care	-	, %	
	(Total	·	
Therapies (n)			
Туре			
Physical therapy	485	,	77.5%
Occupational therapy	435	,	69.5%
Speech therapy	369	,	58.9%
Vision therapy	56	,	8.9%
Aqua-/water therapy	16	,	2.6%
Hippotherapy	14	,	2.2%
Music therapy	14	,	2.2%
Feeding therapy	13	,	2.1%
Applied behavioral analysis	12	,	1.9%
Other	37	,	5.9%
None	64	,	10.2%
Missing	7	,	1.1%
Location/Environment			
Early Intervention/First Steps	81	,	12.9%
Outpatient Center	239	,	38.1%
Hospital	68	,	10.8%
School	382	,	60.8%
Home	22	,	3.5%
Missing	5	,	0.8%
Schooling (n)			
Attend school	524	,	82.8%
Missing	0	,	0.0%
Pull-out classroom	297	,	48.0%
Missing	14	,	2.2%
School therapy/Support			
program			
IEP - any	446	,	71.1%
IEP-Physical therapy	370	,	59.0%
IEP-Occupational therapy	371	,	59.2%
IEP-Speech therapy	340	,	54.2%
504	28	,	4.5%
Missing	6	,	0.9%

Table 9	Therapies a	and schooling	(caregiver-entered)
	i norapies a	and sentooning	(calegiver entered)

IEP – individualized education plan. Missing data percentages are calculated with a denominator of N=633. Other percentages are calculated with a denominator of 633 - n of missing data.

Table 10. Medical specialists, surger	ies, and nu	trition (c				
	n, %, (Total					
	N=633)					
Medical specialists (n)						
Neurosurgery	142 ,	22.4%				
Orthopedic surgery	214 ,	33.8%				
Physiatry	28,	4.4%				
Developmental pediatrics	48,	7.6%				
Psychiatry	51,	8.1%				
Psychology	38,	6.0%				
Gastroenterology	182 ,	28.8%				
Nutrition/Dietician	144 ,	22.7%				
Genetics	79,	12.5%				
Ophthalmology	273 ,	43.1%				
Pulmonology	115 ,	18.2%				
Other	87,	13.7%				
None indicated	99,	15 60/				
Surgeries (n)	7					
Neurosurgical						
Shunt placement/reservoir	106 .	16.7%				
Shunt revision	74 ,	11.7%				
Selective dorsal rhizotomy	69 ,	10.9%				
Deep Brain Stimulation	2,	0.3%				
Intrathecal baclofen pump	4,	0.6%				
Vagal nerve stimulator	10,	1.6%				
Hemispherotomy	6,	0.9%				
Corpus callosotomy	4,	0.6%				
Other	3,	0.5%				
Orthopedic	,					
Arm soft tissue	23,	3.6%				
Leg soft tissue	172 ,	27.2%				
Hip - boney reconstruction	101 ,	16.0%				
Leg - boney reconstruction	27,	4.3%				
Spinal fusion/rods	25,	3.9%				
Other	20 , 37 ,	5.8%				
General/Other	57,	2.070				
G/GJ tube	208,	32.9%				
Strabismus repair	200 , 32 ,	5.1%				
Tracheostomy	26 ,	4.1%				
Myringotomy Tubes	20 , 24 ,	3.8%				
Tonsillectomy/Adenoidectomy	24 , 15 ,	2.4%				
Other	13, 31,	4.9%				
Other	51,	4.7%				

Table 10. Medical specialists, surgeries, and nutrition (caregiver-entered)

None indicated		204	,	32.2%
Nutrition (n)				
	Oral	455	,	77.6%
	G/GJ tube	176	,	30.0%
	Both	45	,	7.7%
	Missing	47	,	7.4%

G/GJ – gastrostomy/gastrojejunostomy. Missing data percentages are calculated with a denominator of N=633. Other percentages are calculated with a denominator of 633 – n of missing data.

Table 11. Seizure history (caregiver-entered)									
	Mean, 95% CI or								
	n,	%	(Total N	=633)					
Has experienced seizures (n)	327	,	51.7%						
Missing	1	,	0.2%						
Seizures are an active issue (n)	291	,	46.1%						
Missing	2	,	0.3%						
Anti-seizure medications (ASMs) (n)									
Levetiracetam	148	,	23.4%						
Clobazam	104	,	16.4%						
Oxcarbazepine	38	,	6.0%						
Topiramate	21	,	3.3%						
Zonisamide	34	,	5.4%						
Epidiolex	20	,	3.2%						
Felbamate	20	,	3.2%						
Lacosamide	18	,	2.8%						
Valproate	11		1.7%						
Other	49		7.7%						
Any ASM	268		42.3%						
2 or more ASMs	147		23.2%						
3 or more ASMs	74		11.7%						
None indicated	23	,	3.6%						
Rescue medication (n)		,							
Diazepam, rectal gel	166		26.2%						
Diazepam, nasal spray	54		8.5%						
Midazolam, nasal spray	10	,	1.6%						
Clonazepam, oral wafer	58	,	9.2%						
None indicated	3	,	0.5%						
Typical duration, minutes (mean, 95%		,		-					
CI)	8.0	,	0.0	17.3					
Less than 5 minutes (n)	149	,	26.3%						
5 minutes or longer (n)	76	•	13.4%						
Missing (n)	66		10.4%						
Longest duration, minutes (mean, 95%		,		_					
CI)	222.6	,	0.0	764.4					
Less than 5 minutes (n)	75	,	13.0%						
5 minutes or longer (n)	158	,	27.5%						
Missing (n)	58	,	9.2%						
Days since last seizure (mean, 95% CI)	379.9	,	275.0	- 484.8					
Less than 30 days (n)	109	,	19.0%						
Less than 365 days (n)	168	,	29.2%						
More than 365 Days (n)	65	,	11.3%						
÷ · · · · · · · · · · · · · · · · · · ·									

Table 11. Seizure history (caregiver-entered)

Missing (n)	58 , 9.2%
Drug refractory seizures (n)	
2 ASMs + seizure in last 30 days	83 , 14.4%
3 ASMs + seizure in last 30 days	48 , 8.3%
Missing (n)	58 , 9.2%

ASM – anti-seizure medication. Missing data percentages are calculated with a denominator of N=633. Other percentages are calculated with a denominator of 633 – n of missing data.

Table 12. Other co-existing symptoms (c	-					
	n, %					
		ıl N	1=633)			
Pain concerns	230	,	36.6%			
Missing	4	,	0.6%			
Sleep concerns	190	,	30.2%			
Trouble falling asleep	108	,	17.1%			
Trouble staying asleep	144	,	22.9%			
Other	124	,	19.7%			
Missing	3	,	0.5%			
Mood/Sensory/Social						
Anxiety	157	,	24.8%			
Depression	33	,	5.2%			
Attention difficulties	156	,	24.6%			
Uncontrollable tantrums	82	,	13.0%			
Aggressive behaviors	97	,	15.3%			
Hair pulling	68	,	10.7%			
Skin scratching/picking	78	,	12.3%			
Picky eating	140	,	22.1%			
Oral aversion	103	,	16.3%			
Will only wear certain clothing materials	35	,	5.5%			
Struggles to keep socks or shoes on	73	,	11.5%			
Avoids or seeks loud noises	195	,	30.8%			
Avoids or seeks bright lights	87	,	13.7%			
Excessively touches items	56	,	8.8%			
Excessively puts items in mouth	120	,	19.0%			
Unaware of where their body is in space	107	,	16.9%			
Has trouble reading facial expressions	113	,	17.9%			
Has trouble detecting other's emotions	113	,	17.9%			
Has trouble making friends their own age	126	,	19.9%			
Has trouble making eye contact with others	121	,	19.1%			
Struggles to accept changes in routine	166	,	26.2%			
Has obsessive attachments to things/topics	125	,	19.7%			
Rocks, swings, or flaps hands	125	,	19.7%			
Other	175	•	27.6%			
None indicated	108		17.1%			
N 1 1 1 1 1 1 1 1 1 1						

Table 12. Other co-existing symptoms (caregiver-entered)

l unity mistory (curegiver ente	n, %					
			V=633)			
Siblings	485	,	78.1%			
Missing	12	,	1.9%			
Siblings with health						
concerns	107	,	17.5%			
Anxiety	15	,	2.5%			
Depression	6	,	1.0%			
Attention difficulties	26	,	4.3%			
Autism	19	,	3.1%			
Intellectual disability	12	,	2.0%			
CP or motor conditions	18	,	3.0%			
Same/similar condition	8	,	1.3%			
Genetic condition	3	,	0.5%			
Seizures/Epilepsy	6	,	1.0%			
Hearing/Vision	6	,	1.0%			
Missing	23	,	3.6%			
Other family history						
СР	46	,	7.3%			
Seizures/Epilepsy	45	,	7.1%			
Autism	70	,	11.1%			
Intellectual disability	37	,	5.8%			
Other childhood-onset						
condition	20	,	3.2%			
None indicated	486	, .1	76.8%			

Table 13. Family history (caregiver-entered)

Table 14. Variables affecting the odds of independent walking, oral nutritive intake, and understandable motor speech by age 5.

understandable motor speech by age 5.									
	GMFCS IV-V		G/GJ-tube feeding			VSS III-IV			
Characteristics that can be	(relative to GMFCS			(relative to oral feeding)			(relative to VSS I-II)		
determined in infancy	III)								
	OR (95% CI)		p	OR (95% CI)		<i>p</i>		95% CI)	p
MRICS - Malformation/	3.5,	1.3-9.7	0.02*	2.9,	0.8-10.0	0.09	6.9,	2.3-20.9	0.001*
Maldevelopment									
MRICS - Normal	0.6,	0.2-2.4	0.5	1.4,	0.3-6.9	0.7	1.1,	0.3-4.0	0.872
MRICS - WM Other	1.5,	0.6-3.4	0.4	1.4,	0.5-3.7	0.5	1.2,	0.5-2.9	0.747
MRICS - WM IVH	1.4,	0.6-3.6	0.4	0.9,	0.3-3.0	0.9	4.5,	1.6-12.2	0.004*
MRICS - WM PVL	2.1,	0.9-4.6	0.07	1.4,	0.5-3.6	0.5	3.3,	1.4-7.9	0.006*
MRICS - GM Cortical	3.9,	1.4-11.3	0.01*	4.1,	1.3-13.0	0.02*	8.5,	2.7-26.8	0.000*
MRICS - GM Basal Ganglia	7.9,	1.7-36.1	0.01*	0.6,	0.1-3.2	0.6	2.6,	0.5-13.0	0.239
/ Thalamus									
MRICS - GM AD Infarction	0.7,	0.1-6.0	0.8	1.1,	0.1-12.2	0.9	3.2,	0.5-20.0	0.206
MRICS - GM Watershed	1.5e9,	0.0- **	1.0	1.0,	0.1-14.6	1.0		0.3-90.9	0.294
Etiology - Infection	11.6,	2.0-66.8	0.006*	3.7,	0.9-15.2	0.074		2.5-259.	0.006*
	,			,			6,	9	
Etiology - Prematurity	0.9,	0.3-3.1	0.9	0.7,	0.2-2.6	0.549	0.6,		0.513
Etiology - Stroke		0.1-1.0	0.05	1.3,	0.3-5.9	0.711	0.4,	0.1-1.9	0.275
Etiology - Trauma	-	0.2-13.1	0.6		0.3-35.1	0.302		0.8-192.	0.068
	,			,			6,	4	
Etiology - Genetic	1.7,	0.6-4.8	0.3	3.1,	1.0-9.9	0.050		2.2-25.8	0.001*
Etiology - Unknown	-	0.3-4.8	0.8	3.6,	0.7-18.7	0.123	1.4,		0.645
Etiology - HIE	1.2,	0.4-4.2	0.7	4.7,	1.3-17.7	0.021	2.9,		0.145
Area deprivation index	1.0,		0.7	1.0,	1.0-1.0	0.451	1.0,	1.0-1.0	0.715
Gestational age (weeks)		0.9-1.1	0.7		0.9-1.2	0.723	,	0.9-1.2	0.245
Delivery (C-Section,	,	0.6-2.0	0.7		0.3-1.1	0.103	,	0.5-1.7	0.835
relative to vaginal)	1.1,	0.0 2.0	0.7	0.0,	0.5 1.1	0.105	0.7,	0.0 1.7	0.055
Birth weight (<1500g,	0.8	0.2-3.0	0.7	15	0.2-10.4	0.684	24	0.5-11.8	0.278
relative to 2500-4000g)	0.0,	0.2-5.0	0.7	1.5,	0.2-10.4	0.00-	2.7,	0.5-11.0	0.270
Birth weight (1500-2500g,	1.2	0.5-3.0	0.7	25	0.8-8.0	0.118	15	0.5-4.1	0.485
relative to 2500-4000g)	1.2,	0.5-5.0	0.7	2.3,	0.8-8.0	0.110	1.5,	0.3-4.1	0.465
-	07	0124	0.6	0.0	0152	0.792	0.5	0.1-2.7	0.202
Birth weight (>4000g, relative to 2500-4000g)	0.7,	0.1-3.4	0.6	0.8,	0.1-5.2	0.783	0.5,	0.1-2.7	0.393
0 ,	1.0	0720	0.2	2.0	0 (()	0.000	1.7	0626	0 277
Initial ICU stay (<1 month,	1.6,	0.7-3.9	0.3	2.0,	0.6-6.2	0.233	1.5,	0.6-3.6	0.377
relative to none)		1007	0.011		10005	0.000		0.0.50	0.100
Initial ICU stay (1-3 months,	3.4,	1.3-8.7	0.01*	6.2,	1.9-20.5	0.003*	2.3,	0.8-6.2	0.108
relative to none)									
Initial ICU stay (4-6 months,	6.4,	1.8-22.8	0.005*	17.0	3.2-89.5	0.001*	3.2,	0.8-12.5	0.096
relative to none)				,					
Initial ICU stay (>6 months,	8.4,	2.1-34.0	0.003*	32.1	5.6-183.5	0.000*	6.6,	1.4-31.1	0.017*

relative to none)			,					
*p<0.05, Wald test, binary logistic regression; **insufficient data to assess. MRICS – MRI								
Classification system,	WM – white mat	ter, GM –	grey matter, HIE	– hypoxic	c ischemic			
encephalopathy, GMF	encephalopathy, GMFCS – Gross Motor Function Classification System (I-III: independently							
ambulatory; IV-V: prin	ambulatory; IV-V: primarily uses a wheelchair to get around), G/GJ –							
gastrostomy/gastrojejunostomy, VSS – Viking Speech Scale (I-II: motor ability to produce								
speech that is typically understandable to familiar and unfamiliar listeners; III-IV: limited or no								
motor ability to produ	ce understandable	speech).						